Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

The data from SLATE v1 will be reviewed during the companys previously announced investor event taking place today at 1:30pm ET.